Introduction

MODE OF ACTION OF FUSIDIC ACID
Fusidic acid was originally isolated from a strain of Fusidium coccineum. It is a steroid-like antibiotic belonging to the class fusidanes, chemically related to cephalosporin P 1 and to helvolic acid. 1 It is usually bacteriostatic, but at higher concentrations may be bactericidal. Bacterial protein synthesis depends on the translocation of peptidyl-transfer RNA from the ribosomal acceptor site to the peptidyl site. This requires protein elongation factor G and hydrolysis of guanosine triphosphate (GTP). At least part of fusidic acid's action reflects its ability to stabilize ribosome-elongation factor-GTP plus inorganic phosphate complexes, thereby inhibiting GTP hydrolysis and blocking elongation of the nascent polypeptide chain. Fusidic acid is most active against Staphylococcus aureus and Staphylococcus epidermidis, including methicillin-resistant strains. Such organisms are generally sensitive to fusidic acid as there is no cross-resistance between this agent and β-lactam antimicrobials.
2,3
MODE OF ACTION OF QUINOLONES
The fluoroquinolones are the only antibiotics that directly inhibit DNA synthesis; by binding to the enzyme-DNA complex, they stabilize DNA-strand breaks created by DNA gyrase and topoisomerase IV. Ternary complexes of drug, enzyme and DNA block progress of the replication fork. Cytotoxicity of fluoroquinolones is likely to be a two-step process first involving conversion of the topoisomerasequinolone-DNA complex to an irreversible form and then generation of a double-strand break by denaturing of the topoisomerase. The molecular factors necessary for the transition from the first to the second step remain unclear, but downstream pathways for cell death may overlap with those used by other bactericidal antimicrobials. 4 Several studies have indicated an antibacterial antagonism between fusidic acid and ciprofloxacin. 5 -7 The aim of this study was to investigate whether in vitro antagonism exists between fusidic acid and some quinolones (ofloxacin, levofloxacin, ciprofloxacin and moxifloxacin) against staphylococci strains.
Materials and methods
In this study, 39 staphylococci strains isolated from various clinical samples (blood, urine and wound tissue) were tested. The sensitivity of these strains to fusidic acid and to the quinolones (ofloxacin, levofloxacin, ciprofloxacin and moxifloxacin) was determined using disk diffusion. The inoculum, equivalent to 0.5 McFarland turbidity standard, was streaked on the surface of Mueller-Hinton agar (MHA) plates (Oxoid Ltd, Basingstoke, UK). Commercial disks containing fusidic acid 10 µg, ofloxacin 5 µg, levofloxacin 5 µg, ciprofloxacin 5 µg and moxifloxacin 5 µg (Oxoid Ltd, Basingstoke, UK) were used to test for antimicrobial susceptibility. The plates were incubated at 35°C for 18 h. Fusidic acid sensitivity was evaluated according to the criteria determined by the Comite de l'Antibiogramme de la Societe Française de Microbiologie, 8 and sensitivity to the other antibiotics was determined according to NCCLS M100-S11 criteria. 9 The S. aureus strain, ATTC 25923, was used as a control. The radii of inhibition zones for each antibiotic disk were measured.
In vitro antagonism between fusidic acid and quinolones was investigated with a disk approximation test 6 in 26 staphylococci strains (15 S. aureus and 11 coagulasenegative staphylococci), all of which were sensitive to all antibiotics. A fusidic acid disk was placed in the centre of the plate, and the different quinolone disks placed around it so that the distance between the fusidic acid and quinolone disks was 2 mm less than the sum of the radii of inhibition zones previously measured. After incubation, a 2 mm or greater narrowing of the inhibition zone diameter of the quinolone disks at their fusidic acid side was considered evidence of in vitro antagonism. These strains were then re-examined by placing the antibiotic disks on streaked MHA plates at different distances apart.
Results
In all the staphylococci strains investigated, the zone-of-inhibition diameter produced around the quinolone disks had been narrowed at the side of the fusidic acid disk. In all 26 strains, quinolones and fusidic acid were antagonist in vitro (Fig. 1) .
Antagonism was best observed when quinolone and fusidic acid disks were placed at a distance of 2 mm or closer than the total of both inhibition zone radii.
Discussion
Fusidic acid has been used to treat staphylococcal infections, including acute and chronic osteomyelitis, septic arthritis, endocarditis, soft-tissue infections including those following burns, and lower respiratory tract infections in patients with cystic fibrosis.
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Fusidic acid is usually administered in combination with other anti-staphylococcal antibiotics. Numerous reports have been published concerning the effect of in vitro combinations of fusidic acid with various antibiotics against staphylococci. Most of these reports were based on a limited number of strains and evaluated by different methods (e.g. disk approximation test, chequer-board titration method, time-kill test 10 ). However, the combinations resulted in an additive, indifferent or antagonistic effect. 1 -3,11 Antagonism between a fluoroquinolone and fusidic acid was first reported by Uri in 1993. 6 A routine laboratory disk susceptibility test of a resistant S. aureus strain revealed truncation of the zone of inhibition around the ciprofloxacin disk, placed by chance in proximity to a fusidic acid disk. Follow-up of this observation, by a planned disk approximation test, showed that there was real antagonism between these two antibacterial agents. The antagonistic effect was presumed to be structure-specific, because antagonism was only associated with those fluoroquinolones containing the cyclopropyl substituent at the N1-position: ciprofloxacin, enrofloxacin, sparfloxacin and WIN 57273. Fluoroquinolones without this substituent, such as enoxacin, norfloxacin, pefloxacin and ofloxacin, were not antagonized by fusidic acid.
In this study, however, antagonism has been determined by fusidic acid against ofloxacin and levofloxacin, flouroquinolones that do not have an N1-cyclopropyl substituent.
Li et al. 12 showed unequivocally an antagonistic interaction between ciprofloxacin and all the protein synthesis inhibitors (PSIs) tested by the fractional maximal effect (FME) method, 11 while the same study yielded variable results with either the conventional checkerboard technique or the time-kill method. The FME method demonstrated a similar degree of antagonism against ciprofloxacin by tetracycline, chloramphenicol and erythromycin, and a much lower level of inhibition by tobramycin. 12 Data from our study and from the study by Li et al. 12 indicate that the antagonism between quinolones and fusidic acid might not arise from constitutional properties.
In most studies that investigated the interaction between fusidic acid and rifampicin or vancomycin, neither synergy nor antagonism were demonstrated in vitro. However, antagonistic interaction between fusidic acid and ciprofloxacin has been reported. 7, 13 Interactions between fusidic acid and penicillins are complex, although antagonism or lack of any effect are the usual outcomes. It has been suggested that combinations of anti-staphylococcal penicillins with fusidic acid may prevent the emergence of fusidic acid-resistant staphylococcal mutants, and such combinations may be clinically effective. 7 Roder and Gutschik 5 In vitro antagonism between fusidic acid and quinolones rifampicin alone and combinations of ciprofloxacin with either fusidic acid or rifampicin against 10 strains of S. aureus by the killing kinetic method. 14 Results showed that each combination killed 2 log 10 colony-forming units fewer than ciprofloxacin alone and, from this, they concluded that fusidic acid, as well as rifampicin, antagonized the bactericidal activity of ciprofloxacin.
Although there are some studies indicating the antagonism between ciprofloxacin and fusidic acid, 5, 6 no study has documented the antagonism between ofloxacin, moxifloxacin or levofloxacin and fusidic acid. So, our finding presumably might be the first. The reason for this interaction and its clinical implications are unclear. Our opinion is that new studies are necessary to establish the clinical importance of the antagonism between fusidic acid and quinolones. Based on the results of this study, it was concluded that the possible antagonistic interaction should be considered while planning any therapy combining fusidic acid and a quinolone.
